Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Safety and Risk of Pharmacotherapy is Scopus-indexed (Q2, CiteScore 0.7), DOAJ. Published by FSBI Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation.
Checked against the index lists dated .
ISSN 2312-7821Verify ISSN ↗2619-1164Verify ISSN ↗
Publisher: FSBI Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (nursing) | 5 / 10 | 55th | Q2 |
| Health Professions (miscellaneous) | 63 / 101 | 38th | Q3 |
| Pharmacy | 35 / 52 | 33rd | Q3 |
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | 39 / 57 | 32nd | Q3 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2021–present, best quartile Q2, CiteScore 0.7.
Safety and Risk of Pharmacotherapy is Q2 in Pharmacology (nursing) (rank 5 of 10), Q3 in Health Professions (miscellaneous) (rank 63 of 101) and Q3 in Pharmacy (rank 35 of 52), by CiteScore 2025. It is ranked in 4 subject areas in all.
Safety and Risk of Pharmacotherapy is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0.7, quartile Q2, 55th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.135, quartile Q4, with an H-index of 5.
Safety and Risk of Pharmacotherapy is published by FSBI Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation. Its print ISSN is 2312-7821 and its online ISSN is 2619-1164.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Safety and Risk of Pharmacotherapy has an h-index of 10 and a 2-year mean of 0.88 citations per paper (OpenAlex). Its Scopus CiteScore is 0.7, quartile Q2. On 2-year citations it ranks #41 of 97 Scopus journals in Health Professions (miscellaneous).
Safety and Risk of Pharmacotherapy published 42 papers in 2025; its busiest recent year was 2023 with 47. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 95 research articles (2024–2026), authors are most often from Russia (97.9%), Ukraine (1.1%) and Libya (1.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.